Clinical Oncology, Instituto do Cancer do Estado de São Paulo, University of São Paulo, Av. Dr. Arnaldo, 251-Cerqueira Cesar, São Paulo, São Paulo CEP 01246-000, Brazil.
Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, Villarroel 170, Barcelona 08036, Spain; University of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
Clin Liver Dis. 2020 Nov;24(4):719-737. doi: 10.1016/j.cld.2020.07.012. Epub 2020 Sep 28.
Sorafenib was the first tyrosine kinase inhibitor (TKI) that showed success in extending survival in patients with advanced hepatocellular carcinoma (HCC). In recent years, additional TKIs have been shown to improve survival and expanded the armamentarium for treating this malignancy. The current landscape includes other classes of drugs, such as immune checkpoint inhibitors and monoclonal antibodies. The challenge is now placed on how to best select, combine, and sequence drugs with the goal of improving efficacy and minimizing toxicities to deliver better outcomes for HCC patients.
索拉非尼是第一种在延长晚期肝细胞癌（HCC）患者生存方面取得成功的酪氨酸激酶抑制剂（TKI）。近年来，其他 TKI 已被证明可改善生存并扩大治疗这种恶性肿瘤的武器库。目前的情况包括其他类别的药物，如免疫检查点抑制剂和单克隆抗体。现在的挑战是如何最好地选择、组合和排列药物，以提高疗效并最大程度地减少毒性，为 HCC 患者带来更好的结果。
